--- title: "Arcturus Therapeutics Holdings (ARCT) news: offering and lawsuit" url: "https://aibio.space/companies/arcturus-therapeutics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "ARCT offering and lawsuit news: Arcturus files $500,000,000 replacement shelf with $187,765,319 ATM prospectus. Arcturus Therapeutics Holdings Inc." --- ARCT Arcturus Therapeutics Holdings Inc. NASDAQ · United States # Arcturus Therapeutics Holdings (ARCT) news ARCT offering and lawsuit news Legal · 2026-08-06 ## [Arcturus sues AbbVie and Capstan over trade secrets, and Capstan counterclaims](https://aibio.space/news/arcturus-sues-abbvie-capstan-trade-secrets-capstan-counterclaims/) Arcturus filed in the Southern District of California on September 23, 2025. Capstan Therapeutics answered with counterclaims against the company and two employees, and no trial date is set. ## Latest Arcturus Therapeutics Holdings news 1. 2026-05-07 Distress [Arcturus Therapeutics reports $213.4 million in cash, sees runway past Q2 2028](https://aibio.space/news/arcturus-therapeutics-reports-213-4-million-cash-sees-runway-past-q2/) Operating expenses fell to $31.0 million from $46.2 million, but revenue fell by $27.3 million and the net loss was approximately $27.0 million. 2. 2025-12-30 Financings [Arcturus files $500,000,000 replacement shelf with $187,765,319 ATM prospectus](https://aibio.space/news/arcturus-files-500-000-000-replacement-shelf-187-765-319-atm/) The at-the-market sales agreement names Cantor Fitzgerald, Wells Fargo Securities and William Blair. As of December 22, 2025, the company had sold 1,179,201 shares under it for about $12 million. 3. 2025-11-12 Distress [Arcturus Therapeutics files NT 10-Q after technical error delays third-quarter report](https://aibio.space/news/arcturus-therapeutics-files-nt-10-q-after-technical-error-delays-third/) Arcturus blamed a technical transmission error for missing the deadline on its September 30, 2025 quarterly report. The notice gives no results, and the company's 2024 annual report shows cash use rising sharply. 4. 2025-11-12 Distress [Arcturus Therapeutics 10-Q gets November 12 filing date after transmission error](https://aibio.space/news/arcturus-therapeutics-10-q-gets-november-12-filing-date-after/) Arcturus says a technical transmission error caused it to miss the 5:30 PM Eastern deadline on November 10, 2025 for its quarterly report. Its commercial product is KOSTAIVE, a COVID-19 vaccine sold in Japan. ## Arcturus Therapeutics Holdings at a glance - **Ticker**: ARCT - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $191.5 million ### Related companies - [Ultragenyx Pharmaceutical](https://aibio.space/companies/ultragenyx-pharmaceutical/) NASDAQ: RARE - [Compass Therapeutics](https://aibio.space/companies/compass-therapeutics/) NASDAQ: CMPX - [Corcept Therapeutics](https://aibio.space/companies/corcept-therapeutics/) NASDAQ: CORT - [Cellectar Biosciences](https://aibio.space/companies/cellectar-biosciences/) NASDAQ: CLRB - [Amphastar Pharmaceuticals](https://aibio.space/companies/amphastar-pharmaceuticals/) NASDAQ: AMPH - [Oragenics](https://aibio.space/companies/oragenics/) AMEX: OGEN - [Retrieve Medical Holdings](https://aibio.space/companies/retrieve-medical/) OTC: RMHI - [Bristol-Myers Squibb](https://aibio.space/companies/bristol-myers-squibb/) NYSE: BMY ### Also on NASDAQ - [Pyxis Oncology](https://aibio.space/companies/pyxis-oncology/) PYXS - [Ernexa Therapeutics](https://aibio.space/companies/ernexa-therapeutics/) ERNA - [MIRA Pharmaceuticals](https://aibio.space/companies/mira-pharmaceuticals/) MIRA - [BridgeBio Pharma](https://aibio.space/companies/bridgebio-pharma/) BBIO - [Whitehawk Therapeutics](https://aibio.space/companies/whitehawk-therapeutics/) WHWK - [ImageneBio](https://aibio.space/companies/imagenebio/) IMA ## What Arcturus Therapeutics Holdings does Arcturus Therapeutics is a messenger RNA medicines company focused on liver and respiratory rare diseases. Its ongoing Phase 2 studies test RNA therapeutic candidates for ornithine transcarbamylase (OTC) deficiency and cystic fibrosis (CF). Its platforms are STARR, a self-amplifying mRNA technology, and LUNAR, a lipid nanoparticle delivery system. Its self-amplifying mRNA COVID-19 vaccine, KOSTAIVE, is approved in Japan, the European Union and the United Kingdom, and commercial sales began in Japan in October 2024. Arcturus partnered the vaccine with CSL Seqirus for COVID-19, influenza and three other infectious diseases, and notes that CSL Limited reported an accounting write-down of approximately $430 million attributable to that collaboration. In its CF program, ARCT-032 completed dosing in the three initially planned cohorts of a Phase 2 multiple ascending dose study. In its OTC program, ARCT-810 is in a Phase 2 double-blind multiple-dose study. Arcturus also reported a Phase 1 trial of a pandemic avian influenza vaccine candidate funded by BARDA. | Product or program | What it is | Stage | |---|---|---| | KOSTAIVE (ARCT-154) | Self-amplifying mRNA COVID-19 vaccine partnered with CSL Seqirus | approved in Japan, the European Union and the United Kingdom | | ARCT-810 | RNA therapeutic for ornithine transcarbamylase deficiency | Phase 2 | | ARCT-032 | Inhaled RNA therapeutic for cystic fibrosis | Phase 2 | | Avian influenza sa-mRNA vaccine candidate | Self-amplifying mRNA vaccine against pandemic avian influenza, BARDA funded | Phase 1 | Summarised from the company's [10-K filed Mar 3, 2026](https://www.sec.gov/Archives/edgar/data/1768224/000119312526088391/arct-20251231.htm). ## Arcturus Therapeutics Holdings annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$82.0 million](https://www.sec.gov/Archives/edgar/data/1768224/000119312526088391/) | [$152.3 million](https://www.sec.gov/Archives/edgar/data/1768224/000119312526088391/) | | Research and development | [$112.2 million](https://www.sec.gov/Archives/edgar/data/1768224/000119312526088391/) | [$195.2 million](https://www.sec.gov/Archives/edgar/data/1768224/000119312526088391/) | | Net income (loss) | [-$65.8 million](https://www.sec.gov/Archives/edgar/data/1768224/000119312526088391/) | [-$80.9 million](https://www.sec.gov/Archives/edgar/data/1768224/000119312526088391/) | | Cash from operations | [-$74.3 million](https://www.sec.gov/Archives/edgar/data/1768224/000119312526088391/) | [-$59.7 million](https://www.sec.gov/Archives/edgar/data/1768224/000119312526088391/) | | Cash and equivalents | [$230.9 million](https://www.sec.gov/Archives/edgar/data/1768224/000119312526338090/) | [$237.0 million](https://www.sec.gov/Archives/edgar/data/1768224/000119312526088391/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $191.5 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Arcturus Therapeutics Holdings Has Arcturus Therapeutics Holdings raised money recently? Our latest story on this, dated Dec 30, 2025: "Arcturus files $500,000,000 replacement shelf with $187,765,319 ATM prospectus". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/arcturus-files-500-000-000-replacement-shelf-187-765-319-atm/). Is Arcturus Therapeutics Holdings involved in a lawsuit? Our latest story on this, dated Aug 6, 2026: "Arcturus sues AbbVie and Capstan over trade secrets, and Capstan counterclaims". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/arcturus-sues-abbvie-capstan-trade-secrets-capstan-counterclaims/). What is the ticker symbol of Arcturus Therapeutics Holdings? Arcturus Therapeutics Holdings Inc. trades under the ticker ARCT on NASDAQ. Where is Arcturus Therapeutics Holdings listed? Arcturus Therapeutics Holdings Inc. is listed on NASDAQ. What is the SEC CIK of Arcturus Therapeutics Holdings? The SEC Central Index Key (CIK) for Arcturus Therapeutics Holdings Inc. is 1768224. Its filings are on SEC EDGAR. How many shares does Arcturus Therapeutics Holdings have outstanding? 28,423,069 shares as of 2026-08-04, per the cover page of its 10-Q filed 2026-08-06. Which country or territory is Arcturus Therapeutics Holdings listed under? Our directory records Arcturus Therapeutics Holdings Inc. under United States. What does Arcturus Therapeutics Holdings do? Our directory classifies Arcturus Therapeutics Holdings Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Arcturus Therapeutics Holdings? The ISIN recorded for Arcturus Therapeutics Holdings Inc. is US03969T1097. Does aibio.space cover Arcturus Therapeutics Holdings? aibio.space lists Arcturus Therapeutics Holdings Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Arcturus Therapeutics Holdings incorporated? SEC records list its state or country of incorporation as DE. What does Arcturus Therapeutics Holdings develop? Arcturus Therapeutics is a messenger RNA medicines company focused on liver and respiratory rare diseases. Its ongoing Phase 2 studies test RNA therapeutic candidates for ornithine transcarbamylase (OTC) deficiency and cystic fibrosis (CF). What is KOSTAIVE (ARCT-154) from Arcturus Therapeutics Holdings? KOSTAIVE (ARCT-154): Self-amplifying mRNA COVID-19 vaccine partnered with CSL Seqirus Stage: approved in Japan, the European Union and the United Kingdom. What is ARCT-810 from Arcturus Therapeutics Holdings? ARCT-810: RNA therapeutic for ornithine transcarbamylase deficiency Stage: Phase 2. What was Arcturus Therapeutics Holdings's revenue last year? $82.0 million for the fiscal year ended Dec 31, 2025, as reported to the SEC. ## Investor discussion: Arcturus Therapeutics Holdings Members talk about Arcturus Therapeutics Holdings (ARCT). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Arcturus Therapeutics Holdings, newest first. Each line links the filing it comes from. 1. 2026-05-07 Distress Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.02,5.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1768224/000119380526000573/e665435_ex99-1.htm) 2. 2025-12-30 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/1768224/000119380525001797/e665045_s3-arct.htm) 3. 2025-11-12 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1768224/000119380525001558/e664959_nt10q-arct.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:ARCT on TradingView](https://www.tradingview.com/symbols/NASDAQ-ARCT/). ## SEC filings and registration - **SEC name**: Arcturus Therapeutics Holdings Inc. - **CIK**: 1768224 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: ARCT (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Accelerated filer
Smaller reporting company - **Business address**: 10285 SCIENCE CENTER DRIVE, SAN DIEGO, CA - **Phone**: 8589002660 - **Shares outstanding**: 28,423,069 as of 2026-08-04 (10-Q filed 2026-08-06) ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1768224/000119380526001277/e665798_8k-arct.htm) filed 2026-09-23 - [8-K](https://www.sec.gov/Archives/edgar/data/1768224/000119380526001130/e665725_8k-arct.htm) filed 2026-08-25 - [10-Q](https://www.sec.gov/Archives/edgar/data/1768224/000119312526338090/arct-20260630.htm) filed 2026-08-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1768224/000119380526001039/e665679_8k-arct.htm) filed 2026-08-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1768224/000119380526000910/e665618_8k-arct.htm) filed 2026-07-02 - [8-K](https://www.sec.gov/Archives/edgar/data/1768224/000119380526000770/e665552_8k-arct.htm) filed 2026-06-05 - [10-Q](https://www.sec.gov/Archives/edgar/data/1768224/000119312526211943/arct-20260331.htm) filed 2026-05-07 - [8-K](https://www.sec.gov/Archives/edgar/data/1768224/000119380526000573/e665435_8k-arct.htm) filed 2026-05-07 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001768224), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Arcturus Therapeutics Holdings Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker ARCT, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Arcturus Therapeutics Holdings Inc. - **Ticker**: ARCT - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US03969T1097 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-ARCT/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/arcturus-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Arcturus Therapeutics Holdings (ARCT) news: offering and lawsuit", 2026-10-31, https://aibio.space/companies/arcturus-therapeutics/